Mizuho Reduces Kura Oncology Price Target Due to Sales Delay

AI Summary

Mizuho Securities has lowered its price target for Kura Oncology from a previous estimate due to delays in sales. This adjustment reflects concerns about the company's revenue generation capabilities in the near term. As a result, there may be implications for investor sentiment and market activity related to Kura Oncology's stock performance. Specific revised price targets and sales forecast figures were not disclosed in the article.